Skip to content
Yog Pharma
GastrointestinalProton pump inhibitor

Omeprazole is a proton pump inhibitor indicated for GERD, erosive esophagitis, duodenal and gastric ulcers and H. pylori eradication. We supply it to US manufacturers of delayed-release capsules and delayed-release tablets (OTC).

CAS73590-58-6345.4 g/molC17H19N3O3S
2D structure of Omeprazole.

Data from PubChem (CID 4594) and FDA’s substance registry

CAS number

73590-58-6

Molecular formula

C17H19N3O3S

Molecular weight

345.4g/mol

FDA UNII

IUPAC name

6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole

InChIKey

SUBDBMMJDZJVOS-UHFFFAOYSA-N

Appearance
White to off-white crystalline powder that melts with decomposition at about 155 °C.
Solubility
Very slightly soluble in water. Freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Unstable in acid and sensitive to heat, light and moisture, so agree on temperature-controlled shipping before the first order. Enteric-coated omeprazole pellets are a different product from the API.

On the US market

Reference product
PrilosecNDA 019810
Approved ANDAs
17 with a marketed product
Approved forms and strengths
  • Delayed-release capsule (pellets) 10 mg, 20 mg, 40 mg
  • Delayed-release tablet 20 mg
  • Delayed-release orally disintegrating tablet 20 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com